preview

Treating Crohn’s Disease

argumentative Essay
1610 words
1610 words
bookmark

This article is a clinical trial, which investigates the formation of antibodies against infliximab when treating Crohn’s disease. It determines that those who have an initial reaction to infliximab already have a high amount of infliximab antibodies in their system and as a result they would not react as well to the treatment for an extended period of time. The aim to gauge the consequence of infliximab antibodies on the treatment of Crohn's disease was achieved by establishing the concentrations of infliximab and infliximab antibodies in patients, also taking note of the patients in which the infusion caused a negative affect. The research pays particular attention to data analysis of the concentration of infliximab and infliximab antibodies in the patients, it is useful as a accessory source, whilst it focuses on the effectiveness as a result of these antibodies, it does not go into detail on the effectiveness of infliximab therapy on the symptoms of Crohn's disease. The trial is limited by the small number of patients undertaking it, hence, to provide more information a more extensive trial is recommended. The source corroborates with other articles found as they often mention the formation of antibodies, which hinder the treatment but do not explain in detail as this article does. This article will not form the basis of this research topic as it focuses more on infliximab antibodies hindering treatment rather than infliximab as a treatment option, however this information is useful as an appendage. This source investigates patients with Crohn's disease who had to increase their infliximab dosage due to a lack of continued response and found that intensification of infliximab treatment was appropriate to regain a clinical... ... middle of paper ... ...’s disease; as a result, the attention is divided between the two drugs rather than focusing solely on infliximab. The small research group in this clinical trial limits the information given, consequently, to gain further accurate evidence a larger number of patients is recommended. This source has a high level of complexity wherein all of the significant variables are thoroughly thought out and discussed to give the most accurate results as possible. It has a high level of detail in terms of result analysis, discussing; clinical efficacy, mucosal healing, histological healing and safety which directly corroborates with the research question as it focuses on the treatment of the symptoms of Crohn’s disease. Although the information is limited by its focus on both infliximab and adalimumab it provides an extensive discussion of results making up for its limitations.

In this essay, the author

  • Describes a clinical trial that investigates the formation of antibodies against infliximab when treating crohn's disease.
  • Explains that the trial is limited by the small number of patients undertaking it, hence, a more extensive trial would be recommended. the source corroborates with other articles found as they often mention the formation of antibodies, which hinder the treatment.
  • Explains that this source investigates patients with crohn's disease who had to increase their infliximab dosage due to a lack of continued response.
  • Explains that the source aims to determine whether intensification of infliximab treatments would be effective and safe in treating patients with crohn's disease who have a loss of response to the treatment.
  • Describes the details of patients who are undergoing an intensified treatment of infliximab in terms of the short-term efficacy, long-lasting efficacies, and safety, as well as the management techniques employed.
  • Explains that this article addresses the long-term effectiveness of infliximab in treating crohn's disease.
  • Opines that this article would help to form the basis of investigation into the research topic as it includes data pertaining to the effectiveness of infliximab in treating crohn's disease.
  • Explains that s undergo a trial to determine the required subsistence of infliximab to sustain clinical remission for patients with crohn's disease.
  • Explains that the trial focuses on three different methods of dosage as explained previously, although more testable methods and dosages exist, this range keeps it manageable while still giving sufficient data.
  • Concludes that the conclusions drawn from this article are useful for the research topic, as many contrasts were made between the placebo group and the groups being given consistent dosages.
  • Evaluates the efficacy of the combination of seton drainage with infliximab for treatment of complex perianal fistulas, which are a main symptom of crohn's disease.
  • Explains that the source is highly useful in this research topic as it goes into detail on the treatment of perianal fistulas, a symptom of crohn's disease.
  • Explains that this source is limited as it focuses solely on adolescents and has a limited number of medical records analysed. it is well referenced with no conflict of interests acknowledged, which supports its validity.
  • Explains that the source focuses on two different methods of treatment for patients with crohn's disease who are no longer responding appropriately to infliximab.
  • Explains that the article discusses the best way in which infliximab can be used to gain a sustained response.
  • Explains that the source has a sound methodology, which is explained and evaluated well, including useful graphs, tables, and flowcharts. it does not focus solely on how the infliximab is effective in treating the symptoms.
  • Concludes that infliximab is very beneficial for patients with crohn's disease but predicts other drugs that are more easily administered may be developed.
  • Explains that the article reviews the current treatment of inflammatory bowel disease with infliximab by examination of past clinical trials.
  • Opines that this source is beneficial to this area of study as it gives a great detail of information on the treatment of crohn’s disease with infliximab, explaining how it works, and giving extensive examples of clinical trials as supportive evidence.
  • Analyzes how the review article summarises some of the significant research undertaken previously and is well referenced for accessibility to these other clinical trials.
  • Explains that a clinical trial compares two treatments for crohn's disease, infliximab and dalimumabe in terms of effectiveness and safety. both treatments seem to be effective and safe as long-term treatments.
  • Compares the efficacy, mucosal healing, histological healing and safety of infliximab and adalimumabe, stating that the small research group in this clinical trial limits the information given.
Get Access